Prasad Raju

CRSP CFO sells 34,972 shares at $60.19 for $2.1M; holds just 6,767 post-trade amid -90.0% revenue decline and -$106.4M net loss

Prasad Raju sold 34,972 shares (83.8% of pre-transaction holdings) at $60.19 on 2026-01-22, exiting nearly the entire position and retaining only 6,767 shares worth $368,757 at the $54.65 current price. The CFO's action occurs against a backdrop of severe operational deterioration: annual revenue collapsed 90.0% to $889.0K quarterly run-rate, the company reported a $-106.4M net loss in its most recent fiscal year, and the stock has declined 28.8% from its 52-week high of $76.78. His cross-ticker track record shows 6 prior sells averaging -2.4% returns over 30 days, and at CRSP specifically he has conducted five prior sales since 2025-12-22, three executed just 16 days before this transaction. The dramatic concentration of sales in a three-week window (2025-12-22 and 2026-01-06 dates, plus this 2026-01-22 sale) combined with the near-total liquidation of his position suggests structured reductions rather than opportunistic selling, yet the company's financial deterioration provides clear contextual weight to the timing.

CFO Prasad Raju sells 29,700 shares at $60.16 avg (81.4% of holdings); company in revenue decline with -$106.4M net loss

Prasad Raju, CFO of CRISPR Therapeutics, executed 3 separate sales totaling 29,700 shares for $1,786,635.87, reducing his holdings from 36,467 shares to 6,767 shares (an 81.4% reduction). The sales occurred at a blended average price of $60.16, which is 6.7% above the current price of $56.40 and near the 52-week high range. The timing of this substantial liquidation warrants attention given CRISPR's underlying business trajectory: the company reported revenue of $889,000.00 in the latest quarter and an annual revenue decline of -90.0% year-over-year, paired with a full-year net loss of -$106,441,000.00. While the sale price itself was not depressed relative to recent trading, the magnitude of the reduction and the company's severe revenue contraction suggest a material shift in the CFO's exposure to the stock. This is the CFO's second concentrated sell event at this ticker within two weeks, following three sales on 2025-12-22, indicating sustained reduction of personal position rather than a one-time adjustment.

CRSP CFO Prasad Raju sold 10,000 shares for $559,548.74 (blended avg $55.95), reducing holdings by 59.6%

Prasad Raju, CFO of CRISPR Therapeutics, executed 3 separate sales on 2025-12-22 totaling 10,000 shares for $559,548.74, reducing his position from 16,767 to 6,767 shares. The sale occurred near the current price level ($56.46), and notably at a time when the stock is -26.5% from its 52-week high of $76.78. The company is operating in a context of significant operational challenges: Revenue contracted 90.0% year-over-year to $889,000.00 in the latest quarter, and the company generated a $-106,441,000.00 net loss, extending unprofitability through the most recent full fiscal year. A CFO disposing of nearly 60% of his holdings in a context of severe revenue contraction and sustained losses warrants investor attention to the underlying financial trajectory and management's perspective on near-term prospects.